IRAK4 kinase inhibitor

By developing a completely new structure of IRAK4 inhibitor compound, the problem of the difficulty in effectively treating diseases mediated by abnormal expression of IRAK4 is solved in the prior art, effective inhibition of IRAK4 kinase is achieved, and a new therapeutic solution is provided.

CN118978528AActive Publication Date: 2024-11-19SHANGHAI SINOV BIOPHARMACEUTICAL CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411060364.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

Existing treatments are difficult to effectively prevent or treat diseases mediated by abnormal expression of IRAK4, such as autoimmune diseases such as rheumatoid arthritis and lupus erythematosus, activated B-cell-like diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and Recurrent non-Hodgkin lymphoma, etc.

Method used

A completely new class of IRAK4 inhibitor compounds were developed to prepare effective IRAK4 inhibitors through specific chemical synthesis routes and used to prepare pharmaceutical compositions to prevent or treat diseases mediated by abnormal IRAK4 expression. This compound has an excellent inhibitory effect on IRAK4 kinase through its specific structure.

Benefits of technology

This compound can effectively inhibit the activity of IRAK4 kinase, providing a treatment plan for diseases mediated by abnormal expression of IRAK4, significantly reducing or blocking IRAK4 signaling, thereby preventing or treating related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978528A_ABST
    Figure CN118978528A_ABST
Patent Text Reader

Abstract

The invention discloses a novel IRAK4 inhibitor compound as shown in a formula (I) and application of the compound to prevention or treatment of IRAK4-mediated diseases, and the application includes but not limited to rheumatoid arthritis, lupus erythematosus and other autoimmune diseases. And activating B cell-like diffuse large B cell lymphoma, chronic lymphocytic leukemia, recurrent non-Hodgkin lymphoma and other lymphoma. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a novel IRAK4 inhibitor compound and use of the compound in preventing or treating IRAK4-mediated diseases. Background Art

[0002] Chronic inflammatory and autoimmune diseases threaten the lives of millions of people worldwide and are associated with abnormal signaling mediated by inflammation. In addition, some diseases, such as type 2 diabetes and cardiovascular disease, are also associated with abnormal signaling mediated by inflammation.

[0003] Interleukin-1 receptor-associated kinase 4 (IRAK4) is a member of the intracellular serine-threonine kinase IRAK family. Other members of the kinase family include IRAK2, IRAK-M and IRAK3. When the interleukin-1 receptor (IL-1R) or Toll-like receptor (TLR) binds to the ligand, IRAK4 can mediate signal transduction and activate the expression of downstream inflammatory factors. TLRs can receive ligand signals generated by the interaction between the body and microorganisms or endogenous substances, as well as the first wave of inflammatory signals and innate immune response signals triggered by these stimuli. TLRs play a very important role in many diseases, including infections and autoinflammatory diseases, as well as many other diseases in humans. Like tumor necrosis factor-α (TNF-α) and other major cytokines, interleukin-1 (IL-1) is a key factor in the inflammatory pathway that can propagate and amplify signals. Since the signaling pathways mediated by TLR, IL-1R and other cytokine receptors have a cross-linking effect, IRAK4, a key signaling factor downstream of the TLR and IL-1R inflammatory pathways, plays an important role in systemic inflammatory responses and can serve as an effective potential target for the treatment of various inflammation-related diseases. Summary of the invention

[0004] The present invention provides a class of IRAK4 inhibitor compounds with a new structure, uses thereof and pharmaceutical compositions containing the same. The compounds have a better inhibitory effect on IRAK4 kinase.

[0005] The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof:

[0006]

[0007] Wherein, R1 is H or halogen, and R2 is H or -NH2.

[0008] The compound represented by formula (I) or a pharmaceutically acceptable salt thereof may be the following compound:

[0009]

[0010] The present invention also provides use of the above compound or a pharmaceutically acceptable salt thereof in preparing an IRAK4 inhibitor.

[0011] The present invention also provides the use of the above compound or a pharmaceutically acceptable salt thereof in preparing a medicament, wherein the medicament is used for preventing or treating a disease mediated by abnormal expression of IRAK4.

[0012] The “diseases mediated by abnormal expression of IRAK4” include, but are not limited to, autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, activated B-cell-like diffuse large B-cell lymphoma, chronic lymphocytic leukemia, relapsed non-Hodgkin's lymphoma and other lymphomas.

[0013] The present invention also provides a pharmaceutical composition, which comprises the above compound or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0014] As used herein, the term "pharmaceutically acceptable salt" refers to a pharmaceutically acceptable organic or inorganic salt of a compound of the present invention.

[0015] As used herein, the term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients comprising the formulation and / or the mammals to be treated therewith.

[0016] Certain compounds in the present invention have chiral carbon atoms, double bonds, carbocyclic rings or heterocyclic rings, and the resulting configurational isomers {optical isomers (e.g., enantiomers, diastereomers, etc.), cis-trans isomers, etc.} and mixtures thereof (e.g., racemates) are all within the scope of protection of the present invention. When certain compounds in the present invention indicate a specific configuration, it means that the configurational isomer exists and is substantially free of other isomers.

[0017] As used herein, the term "inhibitor" refers to a molecule that decreases, blocks, prevents, delays activation, inactivates, desensitizes, or downregulates, for example, a gene, protein, ligand, receptor, or cell.

[0018] As used herein, the term "abnormal expression of IRAK4" refers to an increase in IRAK4 activity caused by signaling through IRAK4. DETAILED DESCRIPTION

[0019] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.

[0020] Example 1

[0021]

[0022] N,N-dimethylformamide dimethyl acetal (3.55 mL, 26.73 mmol) was added to a solution of 2,6-dichloro-4-methylnicotinonitrile (5000 mg, 26.73 mmol) in isopropanol (50 mL). The reaction solution was heated to 65°C and stirred for 18 hours, then cooled to room temperature and filtered. The filter cake was washed with isopropanol (20 mL) and dried to obtain 0004A (2200 mg, 33%). LCMS (ESI) [M+H] + = 242 (LC-MS method A).

[0023] A mixture of 0004A (2200 mg, 9.1 mmol) and concentrated hydrochloric acid (5 mL) was heated to 45°C and stirred for 18 hours. The reaction solution was poured into ice water, and solids precipitated. The solids were filtered and dried to obtain 0004B (1000 mg, 62%). LCMS (ESI) [M+H] + =215.0@1.58min (LC-MS method A).

[0024] 0004B (800 mg, 3.74 mmol) was dissolved in isopropanol (10 mL), the reaction solution was cooled to 0°C, hydrazine monohydrate (1869 mg, 37.4 mmol) was added, and then heated to 55°C and stirred overnight. The reaction solution was cooled to room temperature, filtered, and the filter cake was washed with methanol (5 mL) and dried to obtain 0004C (300 mg, 38%). LCMS (ESI) [M+H] + =211 (LC-MS method A).

[0025] To a solution of 0004C (600 mg, 2.86 mmol) in acetonitrile (40 mL) was added sodium hydroxide solution (7.1 mL, 1 mol / L, 7.14 mmol), and then water (10 mL). The reaction solution was heated to 55 °C and stirred until the solution was clear. The reaction solution was cooled to 0 °C, 7% sodium hypochlorite solution (532 mg, 7.14 mmol) was slowly added, and the reaction was stirred at room temperature overnight. The reaction solution was cooled to 0 °C, 1 mol / L hydrochloric acid solution was added to adjust the pH to 6, and extracted with ethyl acetate (50 mL × 2). The organic phase was washed with water (20 mL × 3) and saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated to obtain 0004D (130 mg, 25%), which was used directly in the next step without purification. LCMS (ESI) [M+H] + =181.1@1.24 min (LC-MS method A).

[0026] 0004D (130 mg, 0.72 mmol) was dissolved in phosphorus oxychloride (10 mL), and the reaction solution was heated to 105 ° C and stirred for 18 hours. The reaction solution was concentrated, saturated sodium bicarbonate solution (10 mL) was added and stirred, and extracted with ethyl acetate (10 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was separated and purified by flash chromatography (ethyl acetate / petroleum ether=0-35%) to obtain 0004E (40 mg, 28%). LCMS (ESI) [M+H] + =199.0@1.809 min (LC-MS method A).

[0027] 0004E (49 mg, 0.248 mmol) and cesium carbonate (161 mg, 0.496 mmol) were added to a solution of 0003B (40 mg, 0.248 mmol) in N,N-dimethylformamide (5 mL), and the reaction solution was stirred at room temperature for 2 hours. Then it was poured into water, extracted with ethyl acetate (10 mL×2), and the organic phase was dried over anhydrous sodium sulfate. Filtered and concentrated, the residue was prepared by flash chromatography (ethyl acetate / petroleum ether=1 / 1) to obtain 0004F (30 mg, 38%). LCMS (ESI) [M+H] + =324.1@1.617 min (LC-MS method A).

[0028] Tris(dibenzylacetone)dipalladium(0) (8.5 mg, 0.0093 mmol), 1,1'-bis(diphenylphosphino)ferrocene (10 mg, 0.0186 mmol), zinc powder (1.2 mg, 0.0186 mmol) and zinc cyanide (22 mg, 0.186 mmol) were added to a solution of 0004F (30 mg, 0.093 mmol) in N,N-dimethylacetamide (3 mL). The reaction solution was heated to 150°C and stirred for 2 hours. The reaction solution was poured into water and extracted with ethyl acetate (10 mL×2). The organic phase was dried over anhydrous sodium sulfate. Filtered and concentrated, the residue was purified by flash chromatography preparation plate separation (ethyl acetate / petroleum ether=1 / 1) to obtain 0004G (25 mg, 86%) LCMS (ESI) [M+H] + =315.1@1.537 min (LC-MS method A).

[0029] Potassium carbonate (22 mg, 0.1592 mmol) was added to a solution of 0004G (25 mg, 0.0796 mmol) in dimethyl sulfoxide (1 mL). The reaction solution was stirred at room temperature for 1 minute, and then hydrogen peroxide solution (0.5 mL) was added, and the reaction was stirred for 10 minutes at room temperature. SB-0004 (24 mg, 90%) was obtained as a white solid by separation and purification using high pressure reverse phase column chromatography (Column Xbridge 21.2*250mm C18, 10um, flowability A: water (10 mmol / L ammonium bicarbonate), B: acetonitrile). LCMS (ESI) [M+H] + =333.1@6.131min(LC-MS method C)1HNMR(400MHz,DMSO-d6)δ9.673(s,1H),8.914( s,1H),8.490(s,1H),8.359(s,1H),8.296(d,J=6.0Hz,1H),7.867(s,1H),7.62 4(d,J=6.4Hz,1H),4.946(d,J=6.0Hz,0.5H),4.813(d,J=5.6Hz,0.5H),4.620( m,1H),4.296(m,1H),4.119(m,1H),2.663(m,1H),1.562(m,2H),1.002(t,3H).

[0030] Example 2

[0031]

[0032] A solution of 0004B (400 mg, 1.87 mmol) in phosphorus oxychloride (10 mL) was heated to 105°C and stirred for 18 hours. The reaction solution was concentrated. Saturated sodium bicarbonate solution (20 mL) was added and stirred, and extracted with ethyl acetate (20 mL×2). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by flash chromatography (ethyl acetate / petroleum ether=0-10%) to obtain 0005A (130 mg, 30%). LCMS (ESI) [M+H] + =233 (LC-MS method A).

[0033] A mixture of 0005A (300 mg, 1.29 mmol) and ammonia (7N methanol solution, 3 mL) was heated to 100°C in a microwave oven for 0.5 hours. The reaction solution was concentrated and the residue was separated and purified by flash chromatography (ethyl acetate / petroleum ether = 0-10%) to obtain 0005B (130 mg, 48%). LCMS (ESI) [M+H] + =214.0@1.684 min (LC-MS method A).

[0034] A solution of 0003B (55 mg, 0.34 mmol), 0005B (72 mg, 0.34 mmol) and cesium carbonate (221 mg, 0.68 mmol) in N,N-dimethylformamide (3 mL) was heated to 70°C and stirred for 2 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by preparative-TLC (petroleum ether / ethyl acetate = 1 / 1) to obtain 0005C (60 mg, 52%, white solid). LCMS (ESI) [M+H] + =339.1@1.72 min (LC-MS method A).

[0035] 0005C (60 mg, 0.177 mmol), tris(dibenzylideneacetone)dipalladium(0) (16 mg, 0.0177 mmol), 1,1'-bis(diphenylphosphino)ferrocene (20 mg, 0.0355 mmol), zinc powder (2 mg, 0.0355 mmol) and zinc cyanide (41 mg, 0.355 mmol) were mixed in N,N-dimethylacetamide (4 mL) and heated to 150°C in a microwave for 1.5 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by preparative-TLC (petroleum ether / ethyl acetate = 1 / 1) to obtain 0005D (40 mg, 68%, white solid). LCMS (ESI) [M+H] + =330.1@1.54 min (LC-MS method A).

[0036] A solution of 0005D (40 mg, 0.121 mmol) and potassium carbonate (33 mg, 0.243 mmol) in dimethyl sulfoxide (1 mL) was stirred at room temperature for 1 minute, and then hydrogen peroxide (0.5 mL) was added. The resulting mixture was stirred at room temperature for 10 minutes. The reaction solution was separated and purified by high pressure reverse phase column chromatography (Column Xbridge 21.2*250mm C18, 10um, flowability A: water (10mmol / L ammonium bicarbonate), B: acetonitrile) to obtain SB-0005 (24 mg, 57%, white solid). LCMS (ESI) [M+H] + =348.1@5.12min (LC-MS method C); 1H NMR (400MHz, DMSO-d6) δ8.925(s,1H),8.094(d,J=5.6Hz,1H),7.797(d,J=2 .8Hz,1H),7.657(d,J=2.4Hz,1H),7.492(s,1H),7.337(d,J=5.6Hz,1H),7. 155(s,2H),4.919(d,J=5.2Hz,0.5H),4.786(d,J=5.2Hz,0.5H),4.597(m,1 H),4.388(m,1H),4.147(m,1H),2.541(m,1H),1.539(m,2H),0.988(t,3H).

[0037] Example 3

[0038]

[0039] A solution of (7R)-7-ethyl-3,3-dimethyltetrahydropyrrolo[1,2-c]oxazol-5(1H)-one (100 mg, 0.21 mmol) and 4-toluenesulfonic acid (115 mg, 0.601 mmol) in acetonitrile (3 mL) was heated to 90°C for 2 hours. The reaction solution was concentrated and the residue was separated and purified by flash chromatography (methanol / dichloromethane = 0-10%) to obtain 0008A (50 mg, 64%). LCMS (ESI) [M+H] + =144.1@1.26 min (LC-MS method A).

[0040] A solution of 0008A (43 mg, 0.303 mmol), 0004E (60 mg, 0.303 mmol) and cesium carbonate (197 mg, 0.606 mmol) in N,N-dimethylformamide (3 mL) was heated to 50°C and stirred for 8 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by preparative-TLC (petroleum ether / ethyl acetate = 1 / 1) to obtain 0008B (20 mg, 22%, white solid). LCMS (ESI) [M+H] + =306.1@1.629 min (LC-MS method B).

[0041] 0008B (30 mg, 0.1 mmol), tris(dibenzylideneacetone)dipalladium(0) (10 mg, 0.01 mmol), 1,1'-bis(diphenylphosphino)ferrocene (10 mg, 0.02 mmol), zinc powder (10 mg, 0.02 mmol) and zinc cyanide (30 mg, 0.2 mmol) were mixed in N,N-dimethylacetamide (2 mL) and heated to 150°C in a microwave for 1.5 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by preparative-TLC (petroleum ether / ethyl acetate = 1 / 1) to obtain 0008C (6 mg, 22%, white solid). LCMS (ESI) [M+H] + =297.1@1.50 min (LC-MS method B).

[0042] A solution of 0008C (6 mg, 0.02 mmol) and potassium carbonate (6 mg, 0.02 mmol) in dimethyl sulfoxide (1 mL) was stirred at room temperature for 1 minute, and then hydrogen peroxide (30% aqueous solution, 0.5 mL) was added. The resulting reaction solution was stirred at room temperature for 10 minutes. The reaction solution was separated and purified by high pressure reverse phase column chromatography (Column Xbridge 21.2*250mm C18, 10um, flowability A: water (10mmol / L ammonium bicarbonate), B: acetonitrile) to obtain SB-0008 (4 mg, 64%, white solid). LCMS (ESI) [M+H] + =315.1@5.30min (method D); 1 H NMR (400MHz, DMSO-d6) δ9.553(s,1H),8.498(s,1H),8.369(s,1H),8.303(d,J=6.0Hz,1H),8.075(s,1H),7.868(s,1H),7.628(d,J=6.0H z,1H),4.559(m,1H),4.449(m,1H),3.993(m,1H),2.231(m,1H),2.099(m,1H),1.589(m,1H),1.357(m,1H),1.233(s,1H),0.932(t,3H).

[0043] Example 4

[0044]

[0045] A solution of 0008A (47 mg, 0.328 mmol), 0005B (70 mg, 0.328 mmol) and cesium carbonate (213 mg, 0.656 mmol) in N,N-dimethylformamide (2 mL) was heated to 50°C and stirred for 8 hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by preparative-TLC (petroleum ether / ethyl acetate = 1 / 1) to obtain 0009A (22 mg, 21%, white solid). LCMS (ESI) [M+H] + =321.1@1.575 min (LC-MS method A).

[0046] 0009A (22 mg, 0.0687 mmol), tris(dibenzylideneacetone)dipalladium(0) (6 mg, 0.0069 mmol), 1,1'-bis(diphenylphosphino)ferrocene (7 mg, 0.0137 mmol), zinc powder (1 mg, 0.0137 mmol) and zinc cyanide (16 mg, 0.137 mmol) were mixed in N,N-dimethylformamide (2 mL) and heated to 150°C in a microwave for two hours. The reaction solution was poured into water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was separated and purified by preparative-TLC (petroleum ether / ethyl acetate = 1 / 1) to obtain 0009B (18 mg, 85%, white solid). LCMS (ESI) [M+H] + =312.1@1.287 min (LC-MS method A).

[0047] A solution of 0009B (18 mg, 0.0578 mmol) and potassium carbonate (16 mg, 0.1157 mmol) in dimethyl sulfoxide (1 mL) was stirred at room temperature for 1 minute. Then hydrogen peroxide (0.5 mL) was added and the resulting mixture was stirred at room temperature for 10 minutes. The reaction solution was separated and purified by preparative HPLC (column type: Xbridge 21.2*250mm C18, 10 μm; mobile phase: A: water (10 mM ammonium bicarbonate) B: acetonitrile) to obtain SB-0009 (6 mg, 31%, white solid). LCMS (ESI) [M+H] + =330.2@5.913min (LC-MS method E) 1H NMR(400MHz,DMSO-d6)δ8.086(m,2H),7.808(s,1H),7.651(s,1H),7.499(s,1H),7.336(d,J=5.2Hz,1H),7.13 6(s,1H),4.517(m,2H),4.049(m,1H),2.199(m,1H),2.038(m,1H),1.551(m,1H),1.234(s,1H),0.887(t,3H).

[0048] Attached analysis method

[0049] 1 H NMR and 19 F NMR spectra were detected on a Bruker AVIII400.

[0050] LCMS was performed on an Agilent 1200HPLC / 6100SQ system using the following conditions:

[0051] Method A: Mobile phase: A: water (0.01% TFA) B: acetonitrile (0.01% TFA); Gradient phase: 5% B increase to 95% B within 1.4 min, 95% B with 1.6 min (total running time: 3 min); Flow rate: 2.3 mL / min; Column type: SunFire C18, 4.6*50 mm, 3.5 μm; Column temperature: 50°C. Detectors: ADC ELSD, DAD (214 nm and 254 nm), ES-API.

[0052] Method B: Mobile phase: A: water (10mM NH4HCO3) B: acetonitrile; Gradient phase: 10% to 95% B within 1.5min, 95% B with 1.5min (total running time: 3min); Flow rate: 1.8mL / min; Column type: XBridgeC18, 4.6*50mm, 3.5um; Column temperature: 50℃. Detectors: ADC ELSD, DAD (214nm and 254nm), MSD (ES-API).

[0053] Method C: Mobile phase: A: water (0.01% TFA) B: acetonitrile (0.01% TFA); Gradient phase: 5% B increase to 95% B within 1.2 min, 95% B with 13.8 min (total running time: 15 min); Flow rate: 2 mL / min; Column type: SunFire C18, 4.6*50 mm, 3.5 μm; Column temperature: 50°C. Detectors: UV (214 nm and 4 nm), MS (ESI, Posmode, 132 to 1500 amu).

[0054] Method D: Mobile phase: A: water (10mM NH4HCO3) B: acetonitrile; Gradient phase: 10% to 95% B within 8min, 95% B with 7min (total running time: 15min); Flow rate: 1mL / min; Column type: XBridge C18, 4.6*50mm, 3.5um; Column temperature: 40℃. Detector: UV (214nm and 4nm), MS (ESI, Pos mode, 132to 1500amu).

[0055] Method E: Mobile phase: A: water (0.01% TFA) B: acetonitrile (0.01% TFA); Gradient phase: 5% B increase to 95% B within 1.2 min, 95% B for 1.8 min, back to 5% B within 0.01 min. (Total running time: 15 min); Flow rate: 2 mL / min; Column type: SunFire C18, 4.6*50 mm, 3.5 μm; Column temperature: 40°C. Detector: UV (214 nm and 4 nm), MS (ESI, Pos mode, 132 to 1500 amu).

[0056] Effect Example IRAK4 kinase activity inhibition detection

[0057] Detection of IC of IRAK4 kinase 50 Staurosporine was used as a positive control compound. This experiment used the mobility shift assay to screen compounds on IRAK4 kinase.

[0058] Preparation of compound concentration gradient: the starting concentration of the test compound is 10 μM, 4-fold dilution, 10 concentrations, and duplicate well detection. Gradient dilution is performed in a 384-well plate to form 10 solutions of different concentrations of 100 times the final concentration. Then 250 nL is transferred to the 384 reaction plate using a pipetting system (Labcyte, Echo550) for use. 250 nL of 100% DMSO is added to the negative control well and the positive control well, respectively. A kinase (Carna, 09-145) solution of 2.5 times the final concentration is prepared using kinase buffer (prepared by Sandia Pharmaceutical Technology (Shanghai) Co., Ltd.). 10 μL of 2.5 times the final concentration of kinase solution is added to the compound well and the positive control well (Staurosporine, selleckchem, S1421), respectively; 10 μL of kinase buffer is added to the negative control well. Centrifuge at 1000 rpm for 30 seconds, shake and mix, and incubate at room temperature for 10 minutes. Use kinase buffer to prepare a mixed solution of ATP (Sigma, A2383) and substrate (Kinase substrate 8, GL, 112396) at 25 / 15 times the final concentration. Add 15 μL of a mixed solution of ATP and substrate at 25 / 15 times the final concentration to start the reaction. Centrifuge the 384-well plate at 1000 rpm for 30 seconds, shake and mix, and incubate at room temperature for the corresponding time. Add 30 μL of stop detection solution (prepared by Sandia Pharmaceutical Technology (Shanghai) Co., Ltd.) to stop the kinase reaction, centrifuge at 1000 rpm for 30 seconds, and shake and mix. Read the conversion rate using a microplate reader (Caliper EZ ReaderⅡ).

[0059] Data Analysis:

[0060] Calculation formula:

[0061]

[0062] %Inhibition is the inhibition rate; Conversion%_sample is the conversion rate reading of the sample;

[0063] Conversion%_min: Mean value of negative control wells, representing the conversion rate readings of wells without enzyme activity;

[0064] Conversion%_max: The mean ratio of the positive control wells, representing the conversion rate reading of the wells without compound inhibition.

[0065] Fitting dose-effect curve:

[0066] The log value of the concentration was used as the X-axis and the percentage inhibition rate was used as the Y-axis. The log (inhibitor) vs. response-Variable slope of the analysis software GraphPad Prism 5 was used to fit the dose-effect curve to obtain the IC value of each compound on the enzyme activity. 50 The calculation formula is as follows: Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC50-X)*HillSlope)), the results are shown in Table 1:

[0067] Table 1

[0068] Compound No. <![CDATA[IC 50 (nM)]]> SB-0004 178 SB-0005 236 SB-0008 2301 SB-0009 964

Claims

1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof: in, R1 is H or halogen, and R2 is H or -NH2.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is:

3. A pharmaceutical composition comprising the compound as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. Use of the compound according to any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, in the preparation of an IRAK4 kinase inhibitor.

5. The use as claimed in claim 4, including autoimmune diseases such as rheumatoid arthritis, lupus erythematosus, activated B-cell-like diffuse large B-cell lymphoma, chronic lymphocytic leukemia, relapsed non-Hodgkin's lymphoma and other lymphomas.

Citation Information

Patent Citations

  • IRAK inhibitors and uses thereof

    CN104582705A

  • IRAK4 inhibitor and use thereof

    CN107531725A